Recent studies have demonstrated that CHD5 expression is epigenetically silenced by promoter DNA hypermethylation in HCC [15], colorectal cancer [33], breast cancer [34], gastric cancer [17], and lung cancer [35]. Here, CHD5 is linked to breast carcinoma.